Concord Biotech Q2 FY27 Earnings Call Transcript Released
Concord Biotech reported Q2 FY27 revenue growth of 25% YoY to ₹309.1 crore and H1 FY27 growth of 26% to ₹566.6 crore. API revenue grew 30% YoY to ₹250.1 crore. The company announced a 1:1 bonus issue and received ANDA approvals for Tofacitinib and Mycophenolate Mofetil Oral Suspension. EBITDA margins were 33.8% in Q2.
The release of the earnings call transcript provides detailed financial performance, strategic updates, and future outlook, which are crucial for investors to assess the company's performance and prospects. Key announcements like revenue growth, bonus issue, and regulatory approvals have a significant impact on investor sentiment.
The company reported strong revenue growth, broad-based performance across product categories, and key regulatory approvals. The announcement also included a bonus issue approval and positive outlook for future growth.
Concord Biotech Limited has released the transcript of its Q2 and H1 FY27 earnings conference call, which was held on October 28, 2026. The call detailed a strong performance for the quarter ended September 30, 2026, with revenues growing 25% year-on-year and 26% for the first half of the year. This growth was broad-based, spanning across all product categories and geographies, with notable performance in immunosuppressants, anti-infectives, antifungals, and oncology. The company also highlighted key developments including ANDA approvals for Tofacitinib and Mycophenolate Mofetil Oral Suspension, a USFDA inspection of its Unit-II formulation facility, and the launch of its dermatology division, Inspira. The board's recommendation of a 1:1 bonus issue was also approved by shareholders. API revenue grew by 30% year-on-year, while formulation revenue increased by 6%. Gross margins saw a contraction of approximately 400 basis points due to increased raw material prices, but the company expects recovery through revenue improvement and cost optimization. EBITDA margins stood at 33.8% for Q2 FY27. The company maintains a zero-debt balance sheet with significant cash reserves. Management expressed confidence in sustaining growth momentum, supported by a strong pipeline and strategic expansion into the US formulation market through Stellon Biotech and exploring CDMO opportunities.
What to do with a filing like this
Concord Biotech Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Concord Biotech Limited. Read the original for the full detail.